-
Numerous published studies have strongly suggested that negative emotions such as depression and anxiety contribute to the development of symptomatic coronary artery heart disease.
-
The FDA has approved the first combination NSAID and proton pump inhibitor.
-
Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery.
-
A topical estradiol emulsion has been approved for treating symptoms of menopause. Currently available estrogen products include pills, patches, and vaginal rings. The new estrogen emulsion provides another option for estrogen therapy. Novavax Inc markets this topical formulation as Estrasorb.
-
The rhythm strip shown in the Figure was obtained from a middle-aged man in severe pain from a musculoskeletal disorder. He was not having chest pain, and had no known history of cardiovascular disease. He had an episode of vomiting shortly before this tracing was recorded. Is there evidence of heart block? If so, what type?
-
Previous research failed to show that the angiotensin II antagonist losartan at 50 mg per day was as effective as captopril in reducing mortality in patients with heart failure after myocardial infarction. This raised the question of whether this new class of drugs may be substituted for ACE inhibitors in treating these high-risk patients.
-
Sleep restriction (to 4 hours a night) resulted in increased appetite, increased cortisol levels, lowered TSH levels, worsened glucose tolerance and lower heart rate variability compared with sleep extension (to 12 hours a night) in young healthy volunteers.
-
A new randomized trial using either a calcium channel blocker or an ACE inhibitor to lower systolic blood pressure to the low 120s prevented cardiac events in patients with coronary artery disease compared with systolic blood pressures around 130.
-
Over a 7-year period, there was a dramatic increase in the isolation of community-acquired MRSA in the San Francisco area. Molecular typing showed movement of community-acquired strains into hospitals.
-
A new non-aluminum, non-calcium, phosphate binder has been approved by the FDA.